PatternsRadar
Sign in

MARKSANSMarksans Pharma Limited

NSE
291.15INR-7.90 (-2.64%)Close · 20 Nov 2026
4 Nov 2026Last results
HealthcareSector
Pharmaceuticals & BiotechnologyIndustry
₹13,194 CrMarket cap
23.6P/E (TTM)
47.5%Delivery

Filings & corporate actions

83 results filed
CSV
Next results · Q3 FY27
Expected 5 Feb 2027 – 13 Feb 2027
Estimate: filed 36–44 days after quarter end, last 5 times
Dividend
₹0.90 per share · last 20 Aug 2026
2026
  • 4 NovresultsResults · Q2 FY27 · consolidated and standalone+4.0%NSE
  • 15 OctshareholdingShareholding · 30 Sept 2026-2.0%NSE
  • 20 AugdividendDividend · ₹0.90 per share-1.9%
  • 12 AugresultsResults · Q1 FY27 · consolidated and standalone+12.1%NSE
  • 20 JulshareholdingShareholding · 30 Jun 2026-0.1%NSE
  • 26 MayresultsResults · Q4 FY26 · consolidated and standalone-2.2%NSE
  • 10 AprshareholdingShareholding · 31 Mar 2026+2.0%NSE
  • 5 FebresultsResults · Q3 FY26 · consolidated and standalone-1.2%NSE
  • 13 JanshareholdingShareholding · 31 Dec 2025+0.3%NSE

Reaction to results · all yearsrose on day 0 in 34 of 77 CSV

QuarterFiledDay 0+5D+20DRel vol
Q2 FY274 Nov 2026+4.0%+6.1%—1.5×
Q1 FY2712 Aug 2026+12.1%+17.2%+18.4%35.8×
Q4 FY2626 May 2026-2.2%-6.1%+0.5%3.6×
Q3 FY265 Feb 2026-1.2%+1.2%-6.2%1.2×
Q2 FY2613 Nov 2025+2.2%+1.8%+2.9%1.7×
Q1 FY2612 Aug 2025-11.1%-13.6%-17.1%8.6×
Q4 FY2519 May 2025-6.6%-0.6%-1.1%1.5×
Q3 FY2511 Feb 2025+1.0%-9.3%-22.7%1.8×
Q2 FY2512 Nov 2024+1.7%+2.7%+3.9%4.4×
Q1 FY2514 Aug 2024+14.0%+22.4%+42.5%9.1×
Q4 FY2430 May 2024+1.4%+6.6%+11.8%1.6×
Q3 FY2413 Feb 2024+0.4%-1.1%-15.8%1.4×
Q2 FY2410 Nov 2023+5.2%+13.2%+31.7%4.7×
Q1 FY2411 Aug 2023-3.6%-4.2%-10.4%1.4×
Q4 FY2331 May 2023+5.2%+10.2%+14.0%6.5×
Q3 FY2313 Feb 2023+3.9%+7.9%+0.1%2.2×
Q2 FY2315 Nov 2022+1.6%+5.3%+19.2%1.7×
Q1 FY2314 Aug 2022+6.0%+2.1%+5.7%4.6×
Q4 FY2231 May 20220.0%-2.7%-9.3%0.6×
Q3 FY2211 Feb 2022-5.8%-7.7%-10.7%1.6×
Q2 FY2210 Nov 2021-6.5%-12.2%-11.1%4.4×
Q1 FY2211 Aug 2021-6.0%-6.9%-8.4%2.5×
Q4 FY2131 May 2021-0.4%-6.5%+17.9%0.4×
Q3 FY218 Feb 2021-5.0%-9.7%-5.3%1.5×
Q2 FY216 Nov 2020-0.6%-2.6%+16.8%1.1×
Q1 FY214 Aug 2020+4.9%+11.5%+8.9%0.1×
Q4 FY202 Jun 2020+9.9%+10.8%+28.5%0.5×
Q3 FY2011 Feb 2020-0.7%-4.7%-38.4%1.2×
Q2 FY2013 Nov 2019-3.0%+1.0%-10.5%1.5×
Q1 FY2012 Aug 2019-8.8%-16.5%-7.1%0.5×
Q4 FY1929 May 2019-7.2%-8.2%-17.6%2.7×
Q3 FY1913 Feb 2019+1.0%-2.9%+3.8%0.6×
Q2 FY1928 Nov 2018-2.8%-7.7%-9.2%0.4×
Q1 FY1920 Aug 2018+1.9%+11.0%+8.5%0.8×
Q4 FY1826 Jun 2018-5.5%+2.7%-5.0%0.6×
Q3 FY1814 Feb 2018-2.8%-6.6%-12.7%0.5×
Q2 FY1822 Nov 2017-0.4%-4.9%-3.0%0.4×
Q1 FY1821 Aug 2017-0.4%+7.2%+22.9%0.7×
Q4 FY1717 Jun 2017-0.6%-5.2%-2.0%0.4×
Q3 FY178 Feb 2017+0.5%-1.4%+20.2%1.7×
Q2 FY1718 Nov 2016-0.9%-0.2%-1.4%0.5×
Q1 FY1729 Aug 2016+1.6%+2.6%+21.0%1.0×
Q4 FY1630 May 2016-6.3%-10.2%-4.7%2.0×
Q3 FY1614 Feb 2016-9.1%-14.8%+2.3%1.1×
Q2 FY1617 Nov 2015+1.4%+6.6%-1.3%0.8×
Q1 FY1610 Aug 2015-0.9%-1.3%-25.5%0.7×
Q4 FY153 Jun 2015+0.5%-1.9%+21.0%0.7×
Q3 FY159 Feb 2015+3.4%+12.4%+5.4%1.5×
Q2 FY155 Nov 2014-3.8%-4.6%-9.9%0.9×
Q1 FY1514 Aug 2014+4.2%+17.8%+38.6%4.6×
Q4 FY1431 May 2014-2.0%+31.5%+32.7%0.5×
Q3 FY144 Feb 2014-2.4%-9.9%-9.4%1.3×
Q2 FY146 Nov 2013+5.0%+17.4%+32.8%2.1×
Q1 FY1429 Jul 2013-4.7%-23.6%-31.9%1.0×
Q4 FY134 Jun 2013+4.8%+8.6%+56.2%1.0×
Q3 FY1318 Feb 2013-2.7%+11.0%+9.6%0.7×
Q2 FY1315 Nov 2012+3.1%+18.7%+115.6%1.7×
Q1 FY1322 Aug 2012-3.3%+3.3%0.0%1.4×
Q4 FY126 Jun 2012+3.6%0.0%+3.6%1.1×
Q3 FY1213 Feb 2012+4.7%-4.7%-16.3%1.7×
Q2 FY1222 Nov 2011-8.1%+8.1%-5.4%0.9×
Q1 FY1216 Aug 2011-4.0%-8.0%-8.0%0.5×
Q3 FY1115 Feb 20110.0%-3.3%-16.4%0.8×
Q2 FY1115 Nov 2010-12.8%-14.9%-25.5%3.1×
Q1 FY1112 Aug 2010-1.2%-1.2%-3.7%0.6×
Q4 FY107 May 2010+4.3%-3.3%-10.9%0.8×
Q3 FY1029 Jan 20100.0%-7.1%-10.7%0.4×
Q2 FY1030 Oct 2009-4.1%+4.1%0.0%1.4×
Q1 FY1031 Jul 2009+1.0%+3.0%+32.0%0.5×
Q3 FY0931 Jan 2009-4.1%-8.3%-11.6%0.6×
Q2 FY0931 Oct 2008+5.3%+34.5%-0.9%1.7×
Q1 FY0931 Jul 2008+2.3%+1.8%-6.1%1.1×
Q4 FY0830 Apr 2008-0.4%-9.2%-15.5%0.6×
Q3 FY081 Feb 2008+4.0%+19.3%+18.4%0.5×
Q2 FY0831 Oct 2007+4.8%+20.3%+41.6%1.0×
Q1 FY0831 Jul 2007-1.8%-0.9%-8.3%1.6×
Q4 FY0730 Apr 2007-3.4%-5.2%-8.6%0.7×
Average-0.3%+1.1%+3.3%

Close-to-close from the session before the filing could trade. Day 0 is the first session after it.

Growth · Q2 FY27

Revenue YoY+30.5%
Profit YoY+43.8%
Interest cost YoY+75.1%
Revenue QoQ+11.8%
Profit QoQ-10.1%
CAGR2Y3Y4Y5Y6Y7Y
Revenue+19.4%+19.3%+19.4%+19.4%+17.2%+19.1%
Profit+27.1%+23.3%+29.5%+17.7%+21.7%+31.8%

Key data

Open296.00
Day range288.40 – 297.20
52-week range155.00 – 350.95
From 52w high-17.0%
RSI (14)40.8
ATR (14)12.53
Volume9.08L
Avg volume (20D)14.58L
Rel volume0.62×
Volatility (1Y)43.5%
Turnover₹26.5Cr
Traded value (NSE)₹26.5Cr
VWAP291.87
SMA 50 / 200314.99 / 250.20
Price band20%

Delivery percentage

Latest · 20 Nov 202647.5%
20-day avg45.3%
1-year avg42.6%
Percentile (own history)62nd
Range10.0–100.0%
Sessions3,448

Over the last 20 sessions MARKSANS settled 45.3% of its traded quantity, which is above average for an NSE equity. Its one-year average is 42.6%, so recent sessions are running 2.7 points higher than usual. The latest session ranks higher than 62% of the 3,448 sessions on record for it.

What delivery percentage measuresScan the whole market on delivery

Dividends, deals & holders

Dividend yield0.31%
Dividend, trailing 12M₹0.90
Paid every year for3 yr
Shareholders2.48L · +0.4% QoQ
Net bulk deals, 30D0.00%
Block deals, 30D₹0
Last bulk buy100 days ago

Performance returns

1D1W1M3M6M1Y
Price-2.64%-8.59%-1.12%-9.26%+34.69%+51.29%

Valuation

Market cap₹13,194 Cr
Market cap (NSE)₹13,197 Cr
Free-float cap₹7,406 Cr
P/E (TTM)23.6
P/E (NSE)24.0
EPS (TTM)12.35
P/B4.0
Net margin (TTM)16.5%
Other income / PBT13.2%
ROE18.6%
Debt / equity0.01
Shares outstanding45.32Cr
Listed21 Jan 2002

Ownership

Promoter43.87%
Promoter Δ QoQ0.00 pp
Public56.13%
FII19.06%
DII5.54%
Pledged0.00%

Quarterly results · consolidated

Q3 FY26Q4 FY26Q1 FY27Q2 FY27
Revenue (₹ Cr)754.4856.1840.8940.2
YoY chg+10.6%+1108.4%+35.6%+30.5%
Net profit (₹ Cr)113.7149.0159.4143.5
YoY chg+8.2%+1542.7%+173.9%+44.8%
Net margin15.1%17.4%19.0%15.3%
EPS2.503.273.473.11

Shareholding over time

By quarter

30 Sept 2026 · promoter 43.87% · public 56.13%
30 Sept 2021: promoter 48.25%31 Dec 2021: promoter 48.25%31 Mar 2022: promoter 48.25%30 Jun 2022: promoter 48.25%30 Sept 2022: promoter 48.60%31 Dec 2022: promoter 49.00%20 Jan 2023: promoter 43.80%31 Mar 2023: promoter 43.85%30 Jun 2023: promoter 43.85%30 Sept 2023: promoter 43.85%31 Dec 2023: promoter 43.85%31 Mar 2024: promoter 43.85%30 Jun 2024: promoter 43.87%30 Sept 2024: promoter 43.87%31 Dec 2024: promoter 43.87%31 Mar 2025: promoter 43.87%30 Jun 2025: promoter 43.87%30 Sept 2025: promoter 43.87%31 Dec 2025: promoter 43.87%31 Mar 2026: promoter 43.87%30 Jun 2026: promoter 43.87%30 Sept 2026: promoter 43.87%
2021-092026-09
  • Promoter
  • Public and others
Promoter
43.87%
Public
56.13%
Promoter change
0.00 pp
Filed
15 Oct 2026
FII
19.06%
DII
5.54%
Promoter pledged
0.00%

Who the public is

Mutual funds
3.72%

-0.64 pp QoQ

Insurance
0.00%

0.00 pp QoQ

FPI
10.44%

+1.59 pp QoQ

Retail ≤ ₹2L
23.42%

-0.91 pp QoQ

HNI > ₹2L
3.63%

-0.09 pp QoQ

NRI
1.49%

-0.04 pp QoQ

Bodies corporate
1.85%

+0.06 pp QoQ

Shareholders
2,47,508

+0.4% QoQ

Major holders

As of 30 Sept 2026
HolderTypeHolding
MARK SALDANHAPromoter · Individual43.80%
ORBIMED ASIA IV MAURITIUS FVCI LIMITEDForeign8.62%
UTI-HEALTHCARE FUNDMutual fund1.66%
Schenelle Megan SaldanhaPromoter · Individual0.03%
SANDRA SALDANHAPromoter · Individual0.02%
Merrill Jean SaldanhaPromoter · Individual0.01%
Marise Ann SaldanhaPromoter · Individual0.00%

Every promoter-group member, and each public holder above 1%, as filed.

Promoter and public shares of total equity, from the pattern filed each quarter. Institutional, pledge and public-breakdown figures come from the filing's XBRL, which most filings before Sep-2021 lack, so they are absent there rather than zero. Changes are against the previous filing.

Dividends

since 18 Sept 2014 CSV
Financial yearPaymentsDeclaredAdjusted
FY2026-271₹0.90₹0.90
FY2025-261₹0.80₹0.80
FY2024-251₹0.60₹0.60
FY2023-241₹0.50₹0.50
FY2022-231₹0.25₹0.25
FY2021-221₹0.25₹0.25
FY2020-211₹0.10₹0.10
FY2019-201₹0.05₹0.05
FY2018-191₹0.05₹0.05
FY2017-181₹0.05₹0.05
FY2016-171₹0.12₹0.12
FY2015-161₹0.12₹0.12
FY2014-151₹0.10₹0.10
Ex-dateRecord dateDeclaredAdjusted
20 Aug 2026—₹0.90₹0.90
1 Aug 2025—₹0.80₹0.80
17 Sept 2024—₹0.60₹0.60
7 Jun 2023—₹0.50₹0.50
19 Aug 2022—₹0.25₹0.25
15 Sept 2021—₹0.25₹0.25
22 Sept 2020—₹0.10₹0.10
19 Sept 2019—₹0.05₹0.05
19 Sept 2018—₹0.05₹0.05
19 Sept 2017—₹0.05₹0.05
22 Sept 2016—₹0.12₹0.12
23 Sept 2015—₹0.12₹0.12
18 Sept 2014—₹0.10₹0.10

Rupees per share by ex-date, from NSE’s corporate actions; the record date is who was paid. Declared is the figure in the filing; adjusted restates it for splits and bonuses since, on the same basis as the price chart. Financial years run April to March.

Book closures & record dates

Loading…

NSE's corporate-action calendar: who held the stock on the record date, or through the book-closure window, was entitled to the dividend, bonus, split or rights named.

Insider trades

Insiders net, 30d
₹0
Insiders net, 90d
₹0
Promoters net, 90d
₹0
Insider buyers, 90d
0
Last promoter buy
3.7 years ago
Disclosures on record
20
13 open-market of the newest 20
By year
BroadcastPersonSideSharesValuePriceHolding before → afterStakeRegulation
6 Jun 2024Sandra SaldanhaOtherBuy63.3K₹89.5L141.482.67L → 3.30L0.07%+0.01 pp7(2)told 6 Jun 2024
4 Jun 2024Sandra SaldanhaOtherBuy47.0K₹68.6L146.012.20L → 2.67L0.06%+0.01 pp7(2)told 4 Jun 2024
22 Aug 2023Arvind SinghOtherBuy3.0K₹3.5L115.75— → 3.0K0.00%7(2)told 18 Aug 2023
22 Aug 2023Arvind SinghOtherSell3.0K₹3.4L114.903.0K → —0.00%7(2)told 18 Aug 2023
22 Aug 2023Arvind SinghOtherSell2.0K₹3.3L163.925.0K → 3.0K0.00%0.00 pp7(2)told 18 Aug 2023
22 Aug 2023Arvind SinghOtherSell6.5K₹7.6L117.0611.5K → 5.0K0.00%0.00 pp7(2)told 18 Aug 2023
16 Mar 2023Sandra SaldanhaOtherBuy1.45L₹96.7L66.6975.2K → 2.20L0.05%+0.03 pp7(2)told 15 Mar 2023
1 Mar 2023Sandra SaldanhaPromoterBuy75.0K₹50.6L67.46180 → 75.2K0.02%+0.02 pp7(2)told 28 Feb 2023
2 Mar 2020Mr. Sebastian PereiraEmployeeSell5.1K₹5.5L108.6041.0K → 35.9K0.00%0.00 pp7(2)told 2 Mar 2020
2 Mar 2020Mr. Sebastian PereiraEmployeeBuy100₹10,463104.6340.9K → 41.0K0.00%0.00 pp7(2)told 2 Mar 2020
2 Mar 2020Mr. Sebastian PereiraEmployeeSell2.8K₹2.7L95.2243.7K → 40.9K0.00%0.00 pp7(2)told 2 Mar 2020
2 Mar 2020Mr. Sebastian PereiraEmployeeSell5.0K₹4.3L85.0848.7K → 43.7K0.00%0.00 pp7(2)told 2 Mar 2020
22 Sept 2016HARSH TREHONEmployeeSell69.9K₹34.8L49.7469.9K → —0.00%7(2)told 21 Sept 2016

SEBI insider-trading disclosures, equity only. Dated by the day NSE broadcast them; the trade itself is often weeks earlier. The figures count promoters, directors and KMPs buying or selling on the exchange — not ESOPs, gifts, transfers within the promoter group or pledges. Stake is the holding after, as filed; the change beneath it scales that by the share counts before and after. Regulation is the PIT clause cited, and “told” the day the insider informed the company.

How the insider figures are countedPromoters buying in the open market, market-wideEvery stock on this session

Filings

CSV
Loading…

Bulk & block deals · 12 Aug 2026

CSV
12 of 47 deals
By year
DateDealClientQuantityPriceValue
12 Aug 2026Sell · bulkMICROCURVES TRADING PRIVATE LIMITED43.50L313.40₹136.3Cr
12 Aug 2026Buy · bulkMICROCURVES TRADING PRIVATE LIMITED43.50L313.24₹136.2Cr
11 Jun 2025Sell · block, also bulkORBIMED ASIA IV MAURITIUS FVCI LIMITED1.03Cr249.95₹256.8Cr
11 Jun 2025Buy · block, also bulkUNIFI CAPITAL PRIVATE LIMITED -BLENDED RANGOLI32.48L249.95₹81.2Cr
11 Jun 2025Buy · block, also bulkUNIFI BLEND FUND 230.00L249.95₹75.0Cr
11 Jun 2025Buy · blockSOCIETE GENERALE9.20L249.95₹23.0Cr
11 Jun 2025Buy · blockBANDHAN MUTUAL FUND6.00L249.95₹15.0Cr
11 Jun 2025Buy · blockUNIFI CAPITAL PRIVATE LIMITED5.94L249.95₹14.8Cr
11 Jun 2025Buy · blockUNIFI BCAD FUND5.60L249.95₹14.0Cr
11 Jun 2025Buy · blockSUBHKAM VENTURES I PRIVATE LIMITED5.37L249.95₹13.4Cr
11 Jun 2025Buy · blockUTI MUTUAL FUND4.14L249.95₹10.4Cr
11 Jun 2025Buy · blockCITIGROUP GLOBAL MARKETS SINGAPORE PTE LIMITED4.00L249.95₹10.0Cr

A bulk deal is a client trading over 0.5% of the company’s shares in a day; a block deal is one large trade in the separate block window. Quantities and prices are as NSE published them, not split-adjusted.

Every stock on this session →

Takeover-code disclosures

Loading…

Filed under SEBI’s takeover regulations when a holding crosses 5% of the company, and again with every 2% it moves after that. Shares and percentages as filed.

Every stock on this session →

Short selling, lending & margin

Loading…

Shares sold short on the day, as brokers reported them to NSE at the close. As reported, not split-adjusted.

Exchange surveillance

20 Nov 2026

No surveillance measure applies to MARKSANS.

Price band: 20% · not in the F&O ban.

From NSE’s daily surveillance, price-band and position-limit files. A stock enters the F&O ban when open interest passes 95% of its market-wide position limit and leaves it below 80%; until then no new positions can be opened. CSV: measures · band changes.

Every stock on this session →

Financials · quarterly statement

₹ crore, as filed
By year
 Q3 FY24Q4 FY24AQ1 FY25Q2 FY25Q3 FY25Q4 FY25AQ1 FY26Q2 FY26Q3 FY26Q4 FY26AQ1 FY27Q2 FY27
Revenue from operations586.1560.0590.6641.9681.870.8620.0720.4754.4856.1840.8940.2
Other income4.816.514.911.127.81.75.621.620.135.225.418.2
Total income590.9576.5605.6653.0709.772.5625.6742.0774.6891.3866.2958.3
Total expenses478.3476.3485.5528.4566.460.9549.0608.6623.9691.3659.6764.8
└ Finance costs3.24.82.92.62.70.36.15.85.96.37.06.8
└ Depreciation22.021.120.419.520.72.323.126.924.324.324.932.1
Profit before tax112.7100.3120.0124.6143.311.676.6133.3150.6200.0206.6193.5
Tax expense29.722.631.026.838.22.518.434.236.951.047.250.0
Net profit83.077.689.197.8105.19.158.299.1113.7149.0159.4143.5
EPS1.841.731.962.132.312.001.292.172.503.273.473.12
Net margin14.15%13.86%15.08%15.23%15.41%12.81%9.39%13.76%15.07%17.41%18.96%15.27%
PBT margin19.22%17.91%20.32%19.41%21.01%16.39%12.35%18.51%19.97%23.36%24.57%20.58%
Tax rate26.36%22.57%25.79%21.54%26.66%21.85%24.02%25.65%24.52%25.48%22.83%25.83%

A audited · R restated by a later filing · negatives in parentheses. EPS and the share count are restated onto the same split-adjusted basis as the price chart, so they can be read against it; every rupee figure is exactly as filed. The balance sheet and cash flow arrive only with the half-year and annual filings, and are in their own section below. Latest filed 4 Nov 2026.

Balance sheet & cash flow · half-yearly

₹ crore, as filed
By year

Balance sheet

 FY23H1 FY24FY24H1 FY25FY25H1 FY26FY26H1 FY27
Total assets2,190.42,313.62,681.02,911.3324.03,442.03,860.94,359.6
Current assets1,675.31,703.51,862.52,078.5220.42,354.22,722.73,012.3
└ Cash & equivalents382.4358.5403.3381.049.6481.6634.1742.0
└ Other bank balances332.5302.1270.3275.720.8184.9355.5319.3
└ Current investments0.50.627.015.40.10.80.062.4
└ Trade receivables416.8449.5453.2552.554.0603.1644.6757.4
└ Inventories484.7530.6617.9758.484.6955.2972.3995.7
Total equity1,765.11,897.02,085.92,305.1248.92,713.63,052.73,367.3
└ Attributable to owners1,745.21,875.62,065.12,281.4246.72,688.03,023.23,332.3
└ Non-controlling interest19.921.420.923.72.225.629.534.9
└ Share capital45.345.345.345.34.545.345.345.3
Borrowings41.635.229.124.02.323.429.629.0
└ Current41.635.229.124.02.323.429.629.0
└ Non-current0.00.00.00.00.00.00.00.0
Trade payables230.6200.3268.3281.630.6284.8336.9393.0
Current liabilities341.0332.7389.8444.147.7454.6527.1600.3
Total liabilities425.3416.6595.0606.275.0728.5808.2992.3
Net debt(673.9)(625.9)(671.5)(648.0)(68.2)(643.9)(960.1)(1,094.6)
Debt / equity0.020.020.010.010.010.010.010.01
Current ratio4.915.124.784.684.625.185.175.02

Cash flow, year to date

 FY23H1 FY24FY24H1 FY25FY25H1 FY26FY26H1 FY27
Operating cash flow237.490.6230.477.120.775.2458.1321.5
└ Capex(53.6)(119.9)(208.8)(76.0)(17.3)(73.2)(130.5)(46.1)
Free cash flow183.8(29.3)21.61.23.42.0327.6275.4
Investing cash flow(259.2)(73.1)(140.8)(50.3)(4.9)(36.5)(248.3)(144.1)
Financing cash flow197.8(41.5)(68.7)(49.2)(6.5)(52.9)(70.9)(69.6)
└ Dividends paid(10.2)(22.7)(22.7)(27.2)(3.0)(36.3)(36.3)(40.8)
└ Buybacks(40.2)0.00.00.00.00.00.00.0
Net change in cash176.0(24.0)20.8(22.3)9.3(14.2)138.4107.9

From the half-year and annual results filings: the balance sheet from September 2022, the cash flow from September 2020. Those are when NSE’s XBRL began to carry each statement; earlier filings have it only in the attached PDF. Cash flow columns are year to date, so an H1 column covers April to September and an FY column the full year. Outflows are in parentheses. Net debt is borrowings less cash, bank balances and current investments; for banks, NBFCs and insurers it, debt to equity and the current ratio are left blank because their statements are not built that way.

Announcements & board meetings

Loading…

As the company filed them with NSE, newest first. Board meetings are dated by the meeting, which is usually a week or more after the intimation.

Every stock on this session →

MARKSANS at a glance

  • MARKSANS closed at ₹291.15 on 20 Nov 2026, -2.64% on the day, +51.3% over one year, 17.0% below its 52-week high of ₹350.95.
  • Delivery was 47.5% of traded quantity on 20 Nov 2026, the 62nd percentile of its own 3,448 sessions with a reading (20-session average 45.3%, 1-year average 42.6%).
  • Market capitalisation is ₹13,194 crore at a trailing P/E of 23.6 (trailing EPS ₹12.35).
  • Q2 FY27 results (consolidated, filed 4 Nov 2026): revenue ₹940 crore (+30.5% year on year), net profit ₹144 crore (+44.8%); the price moved +4.0% on the first session after.
  • Promoters held 43.87% at 30 Sept 2026, unchanged on the previous filing.
  • Q3 FY27 results are expected between 5 Feb 2027 and 13 Feb 2027, going by past filing dates — an estimate, not an announcement.

About

Macro sectorHealthcare
Basic industryPharmaceuticals
ISININE750C01026
SeriesEQ
Listed21 Jan 2002
Former symbolsTASCPHARMA (until 14 Nov 2005)
Former namesTasc Pharmaceuticals Limited (until 14 Nov 2005)
NSE market cap · 17 Nov 2026₹13,871 Cr
Free-float market cap (NSE)₹6,564 Cr
Shares outstanding (NSE)45.32Cr
History from14 Nov 2005
Sessions5,209
Turnover rank#469

Sector history

  1. to 16 Aug 2026Index industry · Healthcare
  2. from 16 Aug 2026Healthcare › Healthcare › Pharmaceuticals & Biotechnology › Pharmaceuticals

NSE’s own classification, by the snapshot it changed on.

Prices are adjusted for splits and bonuses. Delivery figures come from NSE’s daily reports and are unavailable for older sessions. Sourced from the eod2 dataset, last updated 20 Nov 2026.